Related references
Note: Only part of the references are listed.Dissecting the functional outcomes of first episode schizophrenia spectrum disorders: a 10-year follow-up study in the PAFIP cohort
Rosa Ayesa-Arriola et al.
PSYCHOLOGICAL MEDICINE (2021)
Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naive patients with a first-episode of non-affective psychosis
Javier Vazquez-Bourgon et al.
PSYCHOPHARMACOLOGY (2018)
Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis
Miquel Bioque et al.
SCHIZOPHRENIA RESEARCH (2018)
Diet as a hot topic in psychiatry: a population-scale study of nutritional intake and inflammatory potential in severe mental illness
Joseph Firth et al.
WORLD PSYCHIATRY (2018)
Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial
Christy L. M. Hui et al.
LANCET PSYCHIATRY (2018)
Improved Metabolic and Psychiatric Outcomes with Discontinuation of Atypical Antipsychotics in Youth Hospitalized in a State Psychiatric Facility
Leslie Hulvershorn et al.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2017)
Pretreatment Cardiometabolic Status in Youth With Early-Onset Psychosis: Baseline Results From the TEA Trial
Karsten G. Jensen et al.
JOURNAL OF CLINICAL PSYCHIATRY (2017)
Causes and predictors of premature death in first-episode schizophrenia spectrum disorders
Ingrid Melle et al.
WORLD PSYCHIATRY (2017)
Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis
Davy Vancampfort et al.
WORLD PSYCHIATRY (2017)
Impaired Glucose Homeostasis in First-Episode Schizophrenia A Systematic Review and Meta-analysis
Toby Pillinger et al.
JAMA PSYCHIATRY (2017)
Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol
A. Parabiaghi et al.
ACTA PSYCHIATRICA SCANDINAVICA (2016)
Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications
Cenk Tek et al.
EARLY INTERVENTION IN PSYCHIATRY (2016)
Clinical Outcome After Antipsychotic Treatment Discontinuation in Functionally Recovered First-Episode Nonaffective Psychosis Individuals: A 3-Year Naturalistic Follow-Up Study
Jacqueline Mayoral-van Son et al.
JOURNAL OF CLINICAL PSYCHIATRY (2016)
Therapeutic effectiveness and tolerability of aripiprazole as initial choice of treatment in first episode psychosis in an early intervention service: A one-year outcome study
Ashok Malla et al.
SCHIZOPHRENIA RESEARCH (2016)
Metabolic Syndrome in South African Patients with Severe Mental Illness: Prevalence and Associated Risk Factors
Shamima Saloojee et al.
PLOS ONE (2016)
Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors
Rocio Perez-Iglesias et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2014)
Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis
Rocio Perez-Iglesias et al.
SCHIZOPHRENIA RESEARCH (2014)
A four-year naturalistic prospective study of cardiometabolic disease in antipsychotic-treated patients
P. Mackin et al.
EUROPEAN PSYCHIATRY (2012)
Early intervention with second-generation antipsychotics in first-episode psychosis: results of an 8-week naturalistic study
Richard C. Josiassen et al.
EARLY INTERVENTION IN PSYCHIATRY (2010)
Medication Nonadherence and Treatment Outcome in Patients With Schizophrenia or Schizoaffective Disorder With Suboptimal Prior Response
Jean-Pierre Lindenmayer et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone
Rocio Perez-Iglesias et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Share Paper
